Related Experiment Video

Updated: Jun 13, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates

Marina K Roell1, Hassan Issafras, Robert J Bauer

  • 1Preclinical Research Department, XOMA (US) LLC, Berkeley, CA 94710, USA. roell@xoma.com

The Journal of Biological Chemistry
|April 23, 2010
PubMed

Insights

This study introduces a new therapeutic antibody approach that selectively reduces harmful signaling while preserving essential functions. The anti-interleukin-1beta (IL-1beta) antibody XOMA 052 demonstrates context-dependent attenuation, offering a novel therapeutic strategy.

Area of Science:

  • Immunology
  • Pharmacology
  • Biochemistry

Background:

  • Therapeutic antibodies often act as antagonists, blocking cellular signaling pathways.
  • Pathologically high signaling activity requires modulation while preserving homeostatic functions.

Purpose of the Study:

  • To describe a novel approach for therapeutic monoclonal antibodies based on context-dependent attenuation.
  • To investigate the mechanism of the anti-interleukin-1beta (IL-1beta) antibody XOMA 052.

Main Methods:

  • Modulating ligand-receptor binding kinetics rather than complete pathway blockade.
  • Utilizing in vitro cell-based assays to assess antibody effects on IL-1beta activity.
  • Evaluating the binding affinity of XOMA 052 to IL-1beta receptors and regulatory proteins.

Main Results:

  • XOMA 052 reduces IL-1beta affinity for its signaling receptor and co-receptor, but not decoy or inhibitory receptors.
  • The antibody shifts the IL-1beta dose-response curve, decreasing its potency by 20-100 fold.
  • Binding to decoy receptors may prevent antibody-target complex accumulation.

Conclusions:

  • XOMA 052 attenuates IL-1beta activity by decreasing its potency while allowing interaction with clearance and inhibitory receptors.
  • This mechanism enables attenuation in concert with endogenous regulatory pathways.
  • Regulatory antibodies like XOMA 052 represent a new class of therapeutic antibodies with selective signaling modulation.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Transcription Attenuation in Prokaryotes02:42

Transcription Attenuation in Prokaryotes

Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure.  Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...